Startups
Focalis Bio
Focalis Bio, formerly EpilepsyGTx, develops gene therapies for focal refractory epilepsy. Its investigational EPY201 programme uses an adeno-associated viral vector to deliver an engineered potassium channel directly to the seizure focus, aiming to reduce neuronal hyperexcitability without removing or destroying brain tissue. The UCL spinout is preparing clinical evaluation of a potential single-dose therapy and developing a broader pipeline for disorders of neuronal hyperexcitability.
Team
Bernard RavinaIndependent Director |
Caitriona O’RourkeDirector |
Carmine CircelliInvestor Director |
Dimitri KullmannChief Scientific Officer, Scientific Founder and Board Member |
Federica DraghiInvestor Director |
Gabriele LignaniScientific Founder and Scientific Advisor |
Jan ThirkettleInterim Board Chair |
Joanne BroadheadConsultant, CMC and Program Management |
Luiz Almeida SilvaResearch Director |
Matthew WalkerScientific Founder and Scientific Advisor |
Nicolas KoebelChief Executive Officer, Founder and Board Member |
 Simon GoldmanInvestor Director |
Stephanie SchorgeScientific Founder and Scientific Advisor |
Teresa NunesChief Medical Officer |